CSM Announces Pilot Results of Subject Retention and Compliance Services for Clinical Trials
Following the completion of extensive pilot studies involving over 3,000 subjects in several clinical trials, CSM announces results demonstrating the effectiveness of its pioneering services in improving subject retention and compliance.
FARGO, ND -- May 11, 2005 -- Following the completion of extensive pilot studies involving over 3,000 subjects in several clinical trials, CSM announces results demonstrating the effectiveness of its pioneering services in improving subject retention and compliance.
These services employ a team of Clinical Trial Research Pharmacists (CTRP) who serve as a critical communication link between all clinical trial stakeholders (sponsors, CROs, investigators, subjects) throughout the trial, 24 hours a day, 7 days a week. CTRP are licensed pharmacists with expertise in clinical trials, drug issues, and subject counseling. Analysis of data collected during the pilot phase indicates that CTRP counseling helped studies meet or exceed expected subject retention rates in every case. In addition, over half of enrolled subjects per trial had a critical intervention, defined as a CTRP intervention that if left undetected or uncorrected would have compromised the quality of the data point.
The pilot studies showed that CTRP services benefited not only the sponsors, but other key study team members as well. Site monitors noted that the frequent CTRP reports helped escalate and resolve critical subject issues in a timely manner, while clinical research coordinators reported that the personalized service of the CTRP team and their 24/7 availability greatly improved communication and subject satisfaction in the studies.
"We are excited about the data from our pilot studies--it confirms the value of the service. In light of the FDA's recent critical path initiative to speed up the drug development process, we feel that CTRP services are needed now more than ever to facilitate the process, support good subject care, and ensure the best clinical data possible," said Tina Schlecht, Pharm.D., Vice President, Retention and Compliance Services.
CTRP services are currently available domestically and will benefit any clinical trial, especially those that involve a complicated drug regimen, dose titration, or use of a medical device to administer drug, or in trials where subject retention or compliance with protocol directions is critical.
About CSM
CSM is a clinical trial support services company committed to advancing clinical trials for pharmaceutical and biotechnology companies by providing innovative and customized services in the areas of clinical supplies and subject retention and compliance.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
